Tag: Chemotherapy

Occurrence rates of hearing loss, tinnitus similar for cancer survivors who received platinum alone, taxane alone, both platinum and taxane

Overall survival longer with addition of pembrolizumab to chemo in tumors expressing PD-L1 with combined positive score of 10 or more

ctDNA-guided approach to determining the need for adjuvant therapy noninferior to standard management for recurrence-free survival

Findings seen in studies involving patients receiving chemoradiotherapy for nonmetastatic squamous cell carcinoma of head and neck

Median drug price markups across centers ranged from 120 to 630 percent

Event-free survival prolonged and percentage of patients with a pathological complete response higher with addition of nivolumab

Rate of event-free survival higher with neoadjuvant pembrolizumab plus chemo versus chemo alone for early triple-negative breast cancer

Overall survival longer in patients receiving first-line treatment with nivolumab plus chemo or nivolumab plus ipilimumab versus chemo alone

Polygenic score based on single nucleotide polymorphisms in the ara-C pathway genes may predict treatment outcomes

Progression-free, overall survival prolonged with lenvatinib plus pembrolizumab versus treating physician's choice of chemotherapy